Overview
Isolated femoral agenesis/hypoplasia (also known as isolated proximal femoral focal deficiency or isolated femoral deficiency) is a rare congenital limb malformation characterized by the partial or complete absence (agenesis) or underdevelopment (hypoplasia) of the femur (thighbone). The condition may affect one leg (unilateral) or both legs (bilateral), with unilateral involvement being more common. The term 'isolated' indicates that the femoral deficiency occurs without other major associated anomalies, distinguishing it from syndromic forms such as femoral hypoplasia–unusual facies syndrome. Clinically, affected individuals present with significant limb length discrepancy, shortened thigh, and abnormal hip and knee joint mechanics. The degree of severity varies widely, ranging from mild shortening of the femur to near-complete absence of the bone. Associated findings may include hip instability, limited range of motion, abnormal gait, and functional impairment of the affected limb. The condition is apparent at birth and is often detected prenatally through ultrasound imaging. Management is multidisciplinary and depends on the severity of the deficiency and the degree of limb length discrepancy. Treatment options include orthotic devices, prosthetic fitting, limb lengthening procedures (such as distraction osteogenesis using external fixators), and reconstructive surgical interventions. In severe cases, rotationplasty (Van Nes rotation) or amputation followed by prosthetic rehabilitation may be considered to optimize function and mobility. Physical therapy and rehabilitation play an essential role throughout the patient's growth and development. The etiology of isolated femoral agenesis/hypoplasia remains largely unknown in most cases, and it typically occurs sporadically without a clear genetic cause.
Also known as:
Sporadic
Usually appears on its own, not inherited from a parent
Neonatal
Begins at or shortly after birth (first 4 weeks)
FDA & Trial Timeline
10 eventsFirst Affiliated Hospital of Zhejiang University — NA
Kafrelsheikh University — NA
Beijing 302 Hospital — PHASE1
Maria Sklodowska-Curie National Research Institute of Oncology — NA
University Hospital, Strasbourg, France — NA
Chungnam National University Hospital
Yeon Hee Park — PHASE2
Rhaeos, Inc. — NA
University of Freiburg — NA
Rigshospitalet, Denmark
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Isolated femoral agenesis/hypoplasia.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Isolated femoral agenesis/hypoplasia at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Isolated femoral agenesis/hypoplasia.
Community
No community posts yet. Be the first to share your experience with Isolated femoral agenesis/hypoplasia.
Start the conversation →Latest news about Isolated femoral agenesis/hypoplasia
Disease timeline:
New recruiting trial: Cardiac Hemodynamics During Left Ventricular Assist
A new clinical trial is recruiting patients for Isolated femoral agenesis/hypoplasia
New recruiting trial: New CSF Biomarkers for Alzheimer's Disease
A new clinical trial is recruiting patients for Isolated femoral agenesis/hypoplasia
New recruiting trial: Shunt-dependency After aSAH - Role of Early Hyperglycaemia in CSF and Blood
A new clinical trial is recruiting patients for Isolated femoral agenesis/hypoplasia
New recruiting trial: Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
A new clinical trial is recruiting patients for Isolated femoral agenesis/hypoplasia
New recruiting trial: OH2 Injection in Combination With HX008 for Melanoma.
A new clinical trial is recruiting patients for Isolated femoral agenesis/hypoplasia
New recruiting trial: VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A new clinical trial is recruiting patients for Isolated femoral agenesis/hypoplasia
New recruiting trial: NoSeal Trial: Comparing Sealants Versus No Sealant for Preventing CSF Leak After Endonasal Skull Base Surgery
A new clinical trial is recruiting patients for Isolated femoral agenesis/hypoplasia
New recruiting trial: Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing
A new clinical trial is recruiting patients for Isolated femoral agenesis/hypoplasia
New recruiting trial: G-CSF After Chemo-radiation in Patients With Glioblastoma
A new clinical trial is recruiting patients for Isolated femoral agenesis/hypoplasia
New recruiting trial: CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer with Leptomeningeal Disease
A new clinical trial is recruiting patients for Isolated femoral agenesis/hypoplasia
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Isolated femoral agenesis/hypoplasia
What is Isolated femoral agenesis/hypoplasia?
Isolated femoral agenesis/hypoplasia (also known as isolated proximal femoral focal deficiency or isolated femoral deficiency) is a rare congenital limb malformation characterized by the partial or complete absence (agenesis) or underdevelopment (hypoplasia) of the femur (thighbone). The condition may affect one leg (unilateral) or both legs (bilateral), with unilateral involvement being more common. The term 'isolated' indicates that the femoral deficiency occurs without other major associated anomalies, distinguishing it from syndromic forms such as femoral hypoplasia–unusual facies syndrome
How is Isolated femoral agenesis/hypoplasia inherited?
Isolated femoral agenesis/hypoplasia follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Isolated femoral agenesis/hypoplasia typically begin?
Typical onset of Isolated femoral agenesis/hypoplasia is neonatal. Age of onset can vary across affected individuals.
Which specialists treat Isolated femoral agenesis/hypoplasia?
11 specialists and care centers treating Isolated femoral agenesis/hypoplasia are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.